- Home
- ATNF vs ATXI Comparison
ATNF vs ATXI Comparison
Compare ATNF & ATXI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ATNF
- ATXI
- Stock Information
- Founded
- ATNF 2016
- ATXI 2015
- Country
- ATNF United States
- ATXI United States
- Employees
- ATNF N/A
- ATXI N/A
- Industry
- ATNF Biotechnology: Pharmaceutical Preparations
- ATXI Biotechnology: Pharmaceutical Preparations
- Sector
- ATNF Health Care
- ATXI Health Care
- Exchange
- ATNF Nasdaq
- ATXI Nasdaq
- Market Cap
- ATNF 2.6M
- ATXI 3.0M
- IPO Year
- ATNF N/A
- ATXI 2017
- Fundamental
- Price
- ATNF $2.65
- ATXI N/A
- Analyst Decision
- ATNF
- ATXI
- Analyst Count
- ATNF 0
- ATXI 0
- Target Price
- ATNF N/A
- ATXI N/A
- AVG Volume (30 Days)
- ATNF 127.9K
- ATXI 27.6K
- Earning Date
- ATNF 02-13-2025
- ATXI 11-14-2024
- Dividend Yield
- ATNF N/A
- ATXI N/A
- EPS Growth
- ATNF N/A
- ATXI N/A
- EPS
- ATNF N/A
- ATXI N/A
- Revenue
- ATNF N/A
- ATXI N/A
- Revenue This Year
- ATNF N/A
- ATXI N/A
- Revenue Next Year
- ATNF $54.15
- ATXI N/A
- P/E Ratio
- ATNF N/A
- ATXI N/A
- Revenue Growth
- ATNF N/A
- ATXI N/A
- 52 Week Low
- ATNF $1.16
- ATXI $1.60
- 52 Week High
- ATNF $17.75
- ATXI $26.48
- Technical
- Relative Strength Index (RSI)
- ATNF 57.11
- ATXI 43.17
- Support Level
- ATNF $1.79
- ATXI $1.64
- Resistance Level
- ATNF $2.02
- ATXI $1.92
- Average True Range (ATR)
- ATNF 0.18
- ATXI 0.13
- MACD
- ATNF 0.05
- ATXI 0.01
- Stochastic Oscillator
- ATNF 82.47
- ATXI 54.28
About ATNF 180 Life Sciences Corp.
180 Life Sciences Corp is a clinical-stage biotechnology company. It is focused on the development of therapeutics for unmet medical needs in chronic pain, inflammation and fibrosis by employing innovative research, and, where appropriate, combination therapy.
About ATXI Avenue Therapeutics Inc.
Avenue Therapeutics Inc is a specialty pharmaceutical company focused on the development and commercialization of therapies for the treatment of rare and neurologic diseases. It focuses on developing its product candidate, AJ201, for spinal and bulbar muscular atrophy, BAER-101, for the treatment of epilepsy and panic disorders, and IV Tramadol for the management of moderate-to-moderately-severe pain in adults.